Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Other(2)

Detailed Status

unknown2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

completed133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
completednot_applicable

Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

NCT05850507
unknownphase_1

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

NCT06043388
unknownnot_applicable

Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

NCT06025812

Clinical Trials (3)

Showing 3 of 3 trials
NCT05850507Not Applicable

Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Completed
NCT06043388Phase 1

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

Unknown
NCT06025812Not Applicable

Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3